Interview with Head of IR Klaus Sindahl
Interview with Head of IR Klaus Sindahl
Following the release of their Q2 2023 report last week, Hansa Biopharma participated in an event hosted by HC Andersen Capital where Head of Investor Relation Klaus Sindahl presented the report, commented on the highlight from the quarter and took questions.
Klaus Sindahl explained that the current commercial roll out of Idefirix in Europa is on track as the sales growth of Idefirix is accelerating and is expected to continue to do so in the coming quarters as the company now has reimbursement agreements in place in all major European markets, and as donor allocation systems that includes highly sensitized patients waiting for kidney transplants has been put in place in most countries. Klaus Sindahl also commented on the recent provisional approval of Idefirix in Australia which includes transplant from both living and deceased doners which is the first time Hansa Biopharma has received such an approval which increases the market potential.
Following the recent FDA approval of gene therapy product Elevidys for the treatment of Duchenne Muscular Distrophy from Hansa Biopharma’s partner Sarepta Therapeutics, Klaus Sindahl explained that although some analysts were disappointed that the approval was limited to 4–5-year-old children and FDA requested an additional confirmatory trial, the huge financial potential for Hansa Biopharma remains unchanged.
The event also confirmed the potential for the imlifidase technology platform to further broaden the number of indications for which it can be used, as illustrated by the recent announcement of the first patient enrollment – out of 10 - in an investigator-initiated phase 2 trial for the use of imlifidase to treat the autoimmune decease ANCA associated vasculitis.
On the financial side, Klaus Sindahl confirmed that Hansa Biopharma still expects its current cash position will be able to finance the company’s activities until 2025.
You can view or review the event (which is in Danish) at this link: Hansa Biopharma
Disclaimer: HC Andersen Capital receives payment from Hansa Biopharma for a DigitalIR/Corporate Visibility agreement. /Claus Thestrup 9:00 AM 26th of July 2023.
Login required
This content is only available for logged in users
Hansa Biopharma
Hansa Biopharma is a Swedish biotech company with the lead product imlifidase, which is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients. The enzyme may be further developed for use in other types of transplantation, in autoimmune diseases, gene therapy and oncology. So far Idefirix (imlifidase) has been conditionally approved in the EU for highly sensitized kidney transplant patients. Currently, Hansa is conducting a pivotal randomized contro trial in kidney transplantation in the United States and is expecting to commence a pivotal study across the U.S. and EU in the rare autoimmune disease anti-GBM during 2022. Additionally, Hansa’s research and development program is advancing the enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.
Read more on company page